Rob Merriel

As CCO at Hudson, Rob has an overall portfolio responsibility for the management and commercialisation of Institute IP. He has over 35 years of experience working in medical research (Baker IDI and Hudson Institute), healthcare services (Melbourne Health and Southern Health) and commercial organisations (Pacific Dunlop and Deloitte Consulting). He is currently on the Boards of two biotechnology start-up companies, is a non-Executive Director of ASX listed cancer therapeutics company Invion Limited, and has been a Director of two Venture Capital Funds and a Director and Company Secretary of several biotechnology-focused medical research institute spin off companies.

Further, Rob has been the Hudson Institute lead in attracting three separate multi-million dollar investments in the translation of discovery science into new treatments for patients: Investments from Roche Pharmaceuticals, from a Boston based Venture Capital fund and from an Australian Venture Capital fund.